Drug Overview

CCR2/CCR5 antagonist BMS-813160 is a highly advanced, investigational medication. It is classified as a Targeted Therapy and a form of Immunotherapy (often called a “Smart Drug”). Instead of acting like traditional chemotherapy that attacks all fast-growing cells, this medicationccr2 ccr5 antagonist bms 813160 works by changing the environment directly surrounding the tumor. This helps clear the way so your body’s own immune system can step in and fight the cancer.

Generic Name: BMS-813160
US Brand Names: None currently (Investigational Drug)
Drug Class: Dual Chemokine Receptor (CCR2 and CCR5) Antagonist
Route of Administration: Oral (Capsule/Tablet)
FDA Approval Status: Investigational. It is not yet FDA-approved for standard commercial use and is currently available only to patients participating in medical clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

To survive, tumors build a protective “wall” around themselves. They do this by tricking the body’s natural immune system into protecting the cancer instead of destroying it. This area around the tumor is called the Tumor Microenvironment (TME).

At the molecular level, tumors release chemical distress signals called CCL2 and CCL5. These signals travel through your bloodstream and act like magnets for specific white blood cells. These blood cells have special “antennas” on their surface called CCR2 and CCR5 receptors.

When these cells pick up the tumor’s signal, they travel to the cancer and transform into “Tumor-Associated Macrophages” (TAMs) and “Regulatory T-cells” (Tregs). You can think of these as “bad guards.” Their job is to put the brakes on your immune system, shutting down the natural fighter cells (cytotoxic T-cells) that are trying to kill the tumor.

How BMS-813160 works:

BMS-813160 is a dual-action “Smart Drug.” It is designed to perfectly plug up both the CCR2 and CCR5 antennas on these circulating white blood cells. By blocking both receptors at once, the cells can no longer “hear” the tumor’s signals. Because the “bad guards” never arrive, the protective wall around the tumor drops. This allows your natural, cancer-killing T-cells (and other immunotherapy drugs) to rush in and destroy the disease.

FDA Approved Clinical Indications

Because BMS-813160 is an investigational drug, it does not currently have official FDA-approved indications for everyday medical practice. However, it is being actively studied in major clinical trials worldwide.

Oncological uses (Investigational):

Colorectal Cancer: Being studied for advanced stages, often combined with other immunotherapies.
Pancreatic Cancer: Investigated for locally advanced or metastatic pancreatic tumors.
Hepatocellular Carcinoma (Liver Cancer): Being researched for tumors that start in the liver.
Non-Small Cell Lung Cancer (NSCLC): Explored as an add-on treatment to help overcome resistance to standard lung cancer therapies.

Non-oncological uses (Investigational):

There are currently no widely approved or standardized non-oncological uses for this specific clinical trial drug.

Dosage and Administration Protocols

Because the drug is still in clinical trials, the exact dosages are strictly controlled by the study doctors and can vary depending on the specific trial phase and what other drugs it is combined with.

Administration Method	Standard Investigational Dose	Frequency and Schedule
Oral (Capsules/Tablets)	Varies by trial protocol	Usually taken once or twice daily continuously.
Infusion Time	N/A	Swallowed whole with water; no IV required.

Dose Adjustments:

Renal/Hepatic Insufficiency: Because this is an experimental medication, formal FDA dosing rules for liver or kidney problems are not yet finalized. However, trial doctors monitor liver enzymes and kidney function very closely through blood tests. If the liver shows signs of stress, the trial dose is usually paused, lowered, or stopped.

Clinical Efficacy and Research Results

Recent clinical trial data (2020–2025) has focused on how well BMS-813160 works when paired with other powerful immunotherapy drugs (like nivolumab) or standard chemotherapy.

Overcoming Resistance: In early-phase clinical trials for solid tumors like colorectal and pancreatic cancers, researchers have found that adding BMS-813160 helps “wake up” the immune system in patients whose tumors previously resisted standard immunotherapy.
Tumor Response Rates: While large-scale Phase 3 survival rates are still being gathered, Phase 1 and 2 data show encouraging Objective Response Rates (ORR). This means a promising percentage of patients in these trials saw their tumors shrink or stop growing when taking the combination therapy compared to historical data of patients who did not receive the dual antagonist.
Microenvironment Changes: Tissue biopsies taken during recent studies proved that the drug works exactly as intended at the cellular level, showing a massive drop in the number of “bad guard” cells protecting the tumors.

Safety Profile and Side Effects

Because BMS-813160 changes how the immune system behaves and is almost always given with other cancer drugs, patients are watched very closely by their trial team for side effects.

Warnings and Precautions

No Black Box Warning: As an investigational medication, it does not yet carry a formal FDA Black Box Warning. However, doctors monitor patients closely for immune-related reactions and sudden drops in healthy white blood cells.

Common Side Effects (>10%)

Fatigue: Feeling unusually tired, weak, or lacking physical energy.
Gastrointestinal Upset: Nausea, mild diarrhea, or loss of appetite.
Low White Blood Cell Counts: A drop in the specific cells that help fight off bacterial infections.

Serious Adverse Events

Liver Toxicity (Hepatotoxicity): Spikes in liver enzymes (AST/ALT), which means the liver is working too hard or becoming inflamed.
Severe Infections: Because the drug alters immune pathways, there is an increased risk of catching serious infections like pneumonia.
Immune-Related Inflammation: Sometimes, waking up the immune system can cause it to accidentally attack healthy organs (like the lungs or intestines).

Management Strategies:

For Liver Stress: You will have regular blood tests. If your liver numbers climb, your doctor will pause the medication immediately until your body recovers.
For GI Upset: You will be given anti-nausea medications and instructed to drink plenty of fluids to stay hydrated.
For Infections: Doctors may prescribe antibiotics quickly if you develop a fever.

Connection to Stem Cell and Regenerative Medicine

The science behind blocking the CCR2 and CCR5 antennas is a massive focus in the world of advanced regenerative medicine and engineered cellular therapies (like CAR-T cell therapy). Solid tumors are notoriously difficult for engineered stem cells and CAR-T cells to penetrate because the Tumor Microenvironment acts like a dense, suppressive brick wall. By using a drug like BMS-813160 to clear out the protective macrophage cells, researchers believe they can “soften” this wall. Current 2025 research areas are exploring if giving patients a dual antagonist before receiving regenerative stem cell therapies will finally allow those new, healthy cells to successfully enter solid tumors and destroy them from the inside out.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

Complete Blood Count (CBC): To get a baseline of your immune cells before starting.
Comprehensive Metabolic Panel (CMP): To ensure your liver and kidneys are completely healthy enough to handle an experimental drug.
Baseline Imaging (CT/MRI or PET scan): To measure the exact size of your tumors so doctors can accurately track your progress.

Precautions During Treatment

Infection Control: Wash your hands often, avoid large crowds, and stay away from people who are sick. Your immune system is actively changing.
Log Your Symptoms: Because this is a clinical trial drug, keeping a daily notebook of how you feel, your temperature, and your bowel movements is vital for your safety.

“Do’s and Don’ts” List

DO take the medication at the exact same times every day to keep the cancer’s antennas continuously blocked.
DO call your clinical trial coordinator immediately if you develop a fever higher than 100.4°F (38°C).
DON’T take any over-the-counter herbs, supplements, or vitamins without asking your doctor, as they might dangerously interact with the experimental drug.
DON’T miss your scheduled blood draws; they are the absolute only way the medical team can see if the drug is safely working inside your body.

Legal Disclaimer

This guide is intended for informational and educational purposes only and does not constitute medical advice. BMS-813160 is an investigational medication and is not yet approved by the FDA or other global regulatory bodies for standard commercial use. It is only available to patients formally enrolled in approved clinical trials. Always consult with your oncologist or qualified healthcare provider regarding your specific diagnosis, treatment options, and whether participating in a clinical trial is safe and appropriate for you. Never delay or disregard professional medical advice based on information provided in this guide.